Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
This new facility strengthens Latin America as a collaborative hub
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Subscribe To Our Newsletter & Stay Updated
